MOD GRF(1-29) comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
In its half yearly financial report on 26 August 2021, Irish Continental Group, which operates ferries between Great Britain and the Republic of Ireland, expressed concern at the lack of implementation of checks on goods arriving into Northern Ireland from Great Britain, as required under the protocol. The company said that the continued absence of these checks (on goods destined for the Republic of Ireland) is causing a distortion of the level playing field, since goods that arrive directly at the Republic of Ireland's ports from Great Britain are checked on arrival. The implementation of border controls between Great Britain and Northern Ireland was the primary catalyst for the 2021 Northern Ireland riots. An unusual example of internal border controls pertains to customs enforcement within the Schengen area. Even though borders are generally invisible, the existence of areas within the Schengen area but outside the European Union Value Added Tax Area, as well as jurisdictions such as Andorra which are not officially a part of the Schengen area but can not be accessed without passing through it, has resulted in the existence of sporadic internal border controls for customs purposes. Additionally, as per Schengen area rules, hotels and other types of commercial accommodation must register all foreign citizens, including citizens of other Schengen states, by requiring the completion of a registration form by their own hand.
Work on the game began with a Kickstarter funding campaign in 2015, before the developers were acquired by Microsoft Studios in 2018, supporting the developers to work on a version for the Xbox One. We Happy Few received mixed reviews from critics.
=== Ultraviolet (UV) inactivation === UV rays can damage the DNA of living organisms by creating nucleic acid dimers. However, the damages are usually not important due to low penetration of UVs through living tissues. UV rays can be used, however, to inactivate viruses since virus particules are small and the UV rays can reach the genetic material, inducing the dimerisation of nucleic acids. Once the DNA dimerised, the virus particules cannot replicate their genetic material which prevent them from spreading. UV light in combination with riboflavin has been shown to be effective in reducing pathogens in blood transfusion products. Riboflavin and UV light damages the nucleic acids in viruses, bacteria, parasites, and donor white blood cells rendering them unable to replicate and cause disease.
=== Source 2, virtual reality and Half-Life: Alyx (2015–present) === Valve announced the Source 2 engine in March 2015, and ported Dota 2 to Source 2 in September. That year, Valve collaborated with the electronics company HTC to develop the HTC Vive, a VR headset released in 2016. Valve experimented with VR games, and in 2016 released The Lab, a collection of VR minigames. Valve recognized that many players wanted a more ambitious VR AAA game, and began exploring the development of a major VR game. They developed several prototypes, with three further VR projects under development by 2017. Finding that the portal systems of its puzzle series Portal were disorienting in VR, it settled on Half-Life. Walker said that Half-Life 3 had been a "terrifyingly daunting prospect", and the team saw VR as a way to return to the series. Full development of a VR Half-Life game started around late 2016, with the largest team in Valve's history. Valve acquired the 3D audio software developer Impulsonic in January 2017. In April 2018, Valve acquired the independent developer Campo Santo, known for the 2016 adventure game Firewatch. Campo Santo planned to develop its own games under Valve, though it initially helped develop Half-Life: Alyx. In November 2018, Valve released Artifact, a digital collectible card game based on Dota 2, with design by Richard Garfield, the creator of Magic: The Gathering. Artifact had unusual pay-for mechanics to acquire new cards, and did not draw a large playerbase, losing 95% of players months after release.
=== Before blood donation === G-CSF is also used to increase the number of hematopoietic stem cells in the blood of the donor before collection by leukapheresis for use in hematopoietic stem cell transplantation. For this purpose, G-CSF appears to be safe in pregnancy during implantation as well as during the second and third trimesters. Breastfeeding should be withheld for three days after CSF administration to allow for clearance of it from the milk. People who have been administered colony-stimulating factors do not have a higher risk of leukemia than people who have not.
Sources: en.wikipedia.org
(2026) reconstruct the environment of Pleistocene gazelles and Persian fallow deer from the Mughr el-Hamamah site (Jordan) on the basis of isotopic analysis of their teeth, interpret their findings as indicative of conditions that were favorable for human occupations during a humid phase of the Last Glacial cycle, and estimate that the hunting area of Early Upper Paleolithic humans from the site covered ∼36 square kilometers. García-Morato et al. (2026) review the fossil record of small-bodied mammals from Middle to Later Stone Age sites in South Africa, and report evidence of impact of site-specific ecological factors on the composition of the studied assemblages. Sawada et al. (2026) interpret burned bone fragments from the terminal Paleolithic strafa from the Fukui Cave (Japan) as more likely to be evidence of human exploitation of medium-sized artiodactyls than evidene of exploitation of large mammals that became extinct in the Pleistocene. Evidence indicating that deposition of sediments preserving bones of mammals (mostly mammoths) at The Mammoth Site (South Dakota, United States) happened during Marine Isotope Stages 6 and 7 is presented by Mahan et al. (2026). Pym et al. (2026) reconstruct changes of late Pleistocene megafaunal populations from the Isthmus of Panama on the basis of the study of spores of coprophilous fungi from sediments of the La Yeguada lake, providing evidence of three distinct phases of decline and recovery coinciding with shifts in vegetation composition. Asevedo et al.
=== Mid-production reboot === On June 25, Bruce Malmuth left the movie, having only directed thirteen days. Production went dark for three days, after which he was replaced by Craig R. Baxley, who had recently directed I Come in Peace for Diamant. Baxley and Stonebridge were quickly sued for $2 million by Barry & Enright Productions, makers of the TV movie Not of This World, which Baxley had abandoned to take over The Brotherhood, but the dispute was resolved a few weeks later. Malmuth called the split a "non hostile, amicable" one, resulting from his push towards a psychological approach, which Baxley described as "almost too dark". An unnamed crew member told the Los Angeles Times of the influence wielded by Bosworth, and particularly Wichard, on set. Wichard himself took responsibility for streamlining the film, telling the paper: "some 17-year-old kid [was] going to say, 'Oh man, Boz, what are you doing?' I had to sell this movie. I had to give them what they expected." In a 2014 interview, however, Bosworth spoke highly of The Brotherhood's original vision, which had a large subplot dedicated to Huff's family, and deemed that the film would have been better for it. He instead blamed Malmuth and Leonetti's technical mistakes, which supposedly made their footage unusable. Others recalled the axed content in a much less favorable light. In his 2011 memoirs, Henriksen described his original dialogue, which largely consisted of Bible quotes, as "ridiculous", and pleaded with Baxley to let him change it as soon as he arrived.
Another study in day-old domestic chicks showed enhancement of long-term memory retention. A randomized, double-blind, placebo-controlled trial from 2023 showed that daily use of Colostrinin improved scores on 2 of 5 cognitive tests in adults of various ages in Poland over a 4-month period.
=== Non-peptide === Adenosine Anamorelin (ONO-7643, RC-1291, ST-1291) Capromorelin (CP-424391) Ibutamoren (MK-677, MK-0677, L-163191, LUM-201) Macimorelin (AEZS-130, JMV 1843) SM-130686 Note that while ulimorelin is a ghrelin receptor agonist, it is not a GHS as it is peripherally selective and has little or no effect on GH secretion. Likewise, adenosine is capable of eliciting a hunger response as a ghrelin agonist but has little to no effect on GH secretion.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.